Covering the entire disease cycle, from medicine to medicine

It is reported that “Zero Krypton Technology” has recently received a strategic investment from Ali Health. The two parties will jointly build a patient-centered and technological innovation-driven full-disease cycle service platform for Chinese cancer patients. Jointly explore the innovative service model of online oncology specialty drugs, and combine online and offline to provide oncology patients with high-quality medical and health services covering the entire disease cycle, from medicine to medicine.

According to data from the National Health Commission, there are over 3.5 million new cancer cases and over 2 million deaths each year in China. The prevention and control situation is severe. The industry’s demand for innovative drugs and treatment programs in the field of tumor treatment is very urgent. Alibaba Health focuses on “Internet + medicine”, applying the Internet model and technological innovation to the development of scientific research, diagnosis and treatment of major diseases, as well as the development of genetic testing, biological vaccines and other fields. This strategic investment in “Zero Krypton Technology” is a new layout of Alibaba Health in the field of major diseases.

“Zerokrypton Technology” was established in 2014. It is a provider of artificial intelligence and medical big data solutions, providing medical services to society and industries, government departments, medical institutions at all levels, domestic and foreign medical device manufacturers, pharmaceutical companies, etc. Big data overall solution, artificial intelligence auxiliary decision-making system, patient whole-process management, hospital public opinion monitoring and brand building, drug equipment research and development, insurance control fees and other integrated services.

The company completed 1 billion D round financing and 700 million D+ round financing in 2018 and 2020, respectively. Among them, the funds raised from the D+ round of financing are used to further focus on the core business development of new special cancer drugs, and to establish a patient service system that covers the entire disease treatment cycle of patients, with Internet hospitals, offline professional clinics pharmacies, and new drug clinical recruitment as the core. And establish a real-world data platform and innovative insurance payment solutions to assist in the development of new tumor drugs.

According to the data, the current main business of “Zero Krypton Technology” includes real-world drug research, patient health management business, patient recruitment business, etc., and focuses on providing solutions in the field of major diseases represented by tumors and rare diseases. This is consistent with the company’s development plan shown in the D+ round of financing. After this round of financing, “Zerokrypton Technology” will rely on the advantages in data governance, auxiliary diagnosis and treatment, scientific research services, patient management, doctor operations, drug distribution, etc. accumulated in the vertical field of oncology to carry out the connection and integration of various online and offline resources. Get through and establish a closed loop of patient-centered services; connect with Ali Health Platform, Zero Krypton Internet Hospital and Cancer Patient Service Center, etc., to provide users with better services for critical illnesses.

Editor: Cai Shuning

Extended reading:

  • “ZeroKrypton Technology” received 1 billion yuan in D round of financing and entered the “AI + medical big data” unicorn queue
  • Focus on medical big data, “Zero Krypton Technology” completes 700 million yuan in D+ round financing